Could your sleep quality predict Alzheimer's? new study investigates racial differences
NCT ID NCT03814603
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed observational study looked at whether poor sleep quality, specifically slow wave sleep, is linked to brain changes that raise Alzheimer's risk, and whether this link differs between African-American and white older adults. Researchers recruited 210 cognitively normal adults aged 60-75, monitored their sleep at home and in a lab, and used brain scans to measure amyloid plaques, a hallmark of Alzheimer's. The goal was to understand why African-Americans have higher Alzheimer's rates, not to test any treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help explain why African-Americans have a higher risk of Alzheimer's, pointing to sleep as a key factor for future prevention strategies.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all populations or lead to direct interventions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
210 people
The number who actually took part.
- Started
-
Nov 2018
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
210 cognitively normal elderly (Clinical Dementia Rating \[CDR\]=0), self-identified as African-American (AA) or non-Hispanic white (NHW), ages 60 to 75 years, with English as their primary language
- Ages
-
60 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male and female subjects with normal cognition and ages 60 to 75. * Within normal limits on neurological and psychiatric examinations. All subjects enrolled will have a CDR=0. * An informed family member or life-partner (preferably bed-partner) will be interviewed over the phone or on the first or second visit to confirm the reliability of the subject interview. A study partner is preferably a spouse, close friend, or relative. * Self-identified as African-American Black or non-Hispanic white. * All subjects must sign the Alzheimer's Disease Center consent form Exclusion Criteria: * History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders). * Significant history of alcoholism based off of the CAGE questionnaire (\>2) or drug abuse. * History of psychiatric illness (e.g., schizophrenia, bipolar or PTSD) * Lifelong depression and anxiety will be allowed as long as there has been no active depressive episode within the last two years. * Geriatric Depression Scale (short form)\>6. * Insulin dependent diabetes. * Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions based off of the PI's discretion. * Physical impairment of such severity as to adversely affect the validity of psychological testing. * Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging. * Medications affecting cognition or SWS: * Narcotic analgesics. * Chronic use of medications with anticholinergic activity. * Anti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine, pergolide, selegiline). * Others: amphetamines, amphetamine-like compounds, appetite suppressants, phenothiazines, reserpine, buspirone, clonidine, disulfiram, guanethidine, MAO inhibitors, theophylline, tricyclic antidepressants, gabapentin, pregabalin, trazodone, cholinesterase inhibitors, memantine. * Chronic use of antidepressants are allowed. * History of a first-degree family member with early onset (age \<60 years) dementia. * Short sleepers (\< 5 hours a day) and long sleepers (\> 10 hours a day). * OSA (defined as AHI4%\>15 and AHI4%\>5 with Epworth≥10) * Self-identified as US-born Caribbean Black, Caribbean-born Black or African-born Black.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Center for Brain Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier
- Can a home device slow Alzheimer's? pilot study tests pulsed electromagnetic therapy
- Eye scans as a window to the body: study probes retinal imaging across diseases